Lexology April 25, 2024
McDermott Will & Emery

On April 15, the Centers for Medicare & Medicaid Services (CMS) released a fact sheet on the potential national coverage determination (NCD) for pre-exposure prophylaxis (PrEP) using antiretroviral drugs to prevent HIV. CMS did not announce any coverage changes in the fact sheet but is providing advance information to avoid any possible disruptions to beneficiaries should the NCD be issued.

We are closely monitoring this issue and will provide further updates regarding the coverage details and additional guidance in the NCD once it is issued.

Under the proposed NCD, PrEP drugs (which may be covered under Medicare Part D and subject to beneficiary cost-sharing obligations) would be transitioned to Medicare Part B, with no beneficiary cost-sharing obligations. CMS also proposes...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: CMS, Govt Agencies, Insurance, Medicare
Medicare fund's outlook improves on stronger economy, but long-term challenges persist
The patient population most at risk of ED boarding
Opinion: The world is relying on the United States to get value-based drug pricing right
The world is relying on the United States to get value-based drug pricing right
What Should a Transplant-Inclusive Value-Based Kidney Care Model Look Like?

Share This Article